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TO THE EDITOR
The two main layers of human skin are
held together by structures at the
dermal–epidermal junction (DEJ) called
anchoring fibrils (AFs). Without properly
functioning AFs, the adherence between
the epidermis and dermis is compro-
mised. Clinically, this translates into skin
fragility and skin bullae. AFs are com-
posed of type VII collagen (C7) that has
a central triple helical domain (TH)
flanked by a 145-kDa non-collagenous
amino-terminal domain (NC1) and a 30-
kDa carboxyl-terminal domain (NC2)
(Burgeson, 1993). AFs and C7 are
perturbed in recessive dystrohyphen-
qj;phic epidermolysis bullosa (RDEB), a
disease characterized clinically by skin
fragility, skin bullae, scarring, and nail loss
(Fine et al., 2008). RDEB is caused by
mutations in the COL7A1 gene encoding
C7. Over 700 mutations have been
identified in DEB patients (Wertheim-
Tysarowska et al., 2012). According to a
recent consensus report, RDEB is clas-
sified as RDEB, severe, generalized
(RDEB-sev, gen), RDEB, generalized,
Table 1. Summary of the clinical and mutational analysis of RDEB patients
Patient ID Patient age Allele 1/allele 2 Mutation location Consequences Clinical diagnosis
1 24 G2517KfsX3/G2517KfsX3 TH/TH PTC/PTC RDEB-sev,gen
2 6 c.356_357delCA/c.356_357delCA CMP/CMP PTC/PTC RDEB-sev,gen
3 10 c.356_357delCA/c.356_357delCA CMP/CMP PTC/PTC RDEB-sev,gen
4 27 c.4172dupC/c.4182-4188dup7 TH/TH PTC/PTC RDEB-sev,gen
5 25 c.5048-5051dup4/c.6501G-A TH/TH PTC/in-frame Del RDEB-sev,gen
6 24 c.2993-5_3007dup20/IVS64þ 4A4G Fn3/TH PTC/Spl RDEB-sev,gen
7 36 c.2993-5_3007dup20/IVS64þ 4A4G Fn3/TH PTC/Spl RDEB-sev,gen
8 11 R578X/R578X Fn3/Fn3 PTC/PTC RDEB-sev,gen
9 5 P1523HfsX187/IVS85-1G4T TH/TH PTC/Spl RDEB-sev,gen
10 3 R613X/R1683X Fn3/TH PTC/PTC RDEB-sev,gen
11 34 c.7787delG/c.7787delG TH/TH PTC/PTC RDEB-sev,gen
12 27 IVS17-2delA/R2814X Fn3/acidic Spl/PTC RDEB-sev,gen
13 22 R236X/IVS85-1G4A Fn3/TH PTC/Spl RDEB-sev,gen
14 37 R2069C/6501G-A TH/TH Mis/in-frame Del RDEB-I
15 23 R578X/G1907D Fn3/TH PTC/Mis RDEB-I
16 28 IVS66þ 1G4C/G2719A TH/TH PTC/Mis RDEB-I
17 62 R2069C/IVS5þ 1G4A TH/CMP Mis/PTC RDEB-I
18 11 G1907D/c.6311_6312delCT TH/TH Mis/PTC RDEB-I
19 38 G1907D/R1933X TH/TH Mis/PTC RDEB-I
20 4 c.4919delG/G2366V TH/TH PTC/Mis RDEB-O
21 45 c.3582-3583delAG/G1782R VWA/TH PTC/Mis RDEB-O
22 31 G2233S/IVS64-2_-1delAG TH/TH Mis/Spl RDEB-O
Abbreviations: CMP, cartilage matrix protein; Del, deletion; Fn3, fibronectin type III-like repeats; Mis, missense; RDEB-sev, gen, RDEB, severe, generalized
(formally Hallopeau-Simens RDEB); RDEB-O, RDEB, generalized, other (formerly non-Hallopeau-Simens RDEB); RDEB-I, inversa type of RDEB; PTC,
premature termination codon; Spl, splicing; TH, triple helical domain; VWA, A domain of von Willebrand factor (VWF-A).
Newly identified mutations are indicated in bold.
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Abbreviations: AF, anchoring fibril; C7, type VII collagen; CMP, cartilage matrix protein; DEJ, dermal–
epidermal junction; DIF, direct immunofluorescence; EBA, epidermolysis bullosa acquisita; Fn3,
fibronectin type III-like repeat; IIF, indirect immunofluorescence; NC1, N-terminal noncollagenous domain
of type VII collagen; NC2, C-terminal noncollagenous domain of type VII collagen; PTC, premature
termination codon; RDEB, recessive dystrophic epidermolysis bullosa; RDEB-I, RDEB inversa; RDEB-O,
RDEB generalized other; RDEB-sev,gen, RDEB severe, generalized; TH, triple helical; VWF-A, A domain of
von Willebrand factor
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other (RDEB-O), and RDEB inversa
(RDEB-I) (Fine et al., 2008).
There is also an acquired type of EB
called epidermolysis bullosa acquisita
(EBA). EBA patients are born with nor-
mal skin and then during middle age,
they inappropriately generate IgG anti-
bodies against their C7 and AFs (Yaoita
et al., 1981; Woodley et al., 1984),
leading to skin fragility, trauma-indu-
ced blisters, and scarring reminiscent
of hereditary RDEB. The conventional
wisdom in Dermatology is that patients
with genetic RDEB may have a clinical
phenotype resembling EBA, but that
they have no auto-antibodies against
C7. In this study, we identified 22
patients with bona fide RDEB, and
characterized their mutations and their
disease phenotype clinically, pathologi-
cally, ultrastructurally, and immunologi-
cally. We sought to determine whether
any of these RDEB patients had anti-C7
antibodies in their sera or skin.
As summarized in Table 1, 13 of the
patients were classified as RDEB-sev, gen
(patients 1–13) with COL7A1 mutations
that created premature termination
codons (PTCs) due to nonsense or splice-
site mutations (Spl), small insertions, or
deletions. Another nine RDEB patients
(patients 14–22) had missense mutations
(Mis) in one allele of COL7A1 predicting
glycine or arginine substitutions in the TH
domain. Six patients (patients 14–19) had
mutations associated with RDEB-I. Three
patients had RDEB-O (patients 20–22). Of
the 22 sequenced RDEB patients, 32
mutant alleles were identified. Nearly
one-third (10 of 32) of these mutations
have not been previously reported.
We assessed the level of C7 expres-
sion at the DEJ of their skin by immuno-
fluorescence staining of peri-lesional
skin with a rabbit-anti-NC1 antibody
(Chen et al., 1997). As summarized in
Table 1 and Supplementary Figure S1
online, nine patients (patients 14–22)
expressed C7 at the same level as skin
from normal human subjects. The other
RDEB patients had reduced (patients 1,
Table 2. Summary of C7 expression and AFs in recessive dystrophic epidermolysis bullosa patients’ skin and anti-C7
antibodies in the blood
AF by electron microscopy
Patient ID C7 expression at DEJ Density Morphology
NC1/NC2
ELISA C7 ELISA C7 western blot Epitope
1 Reduced þ Very thin and wispy ± þ þ NC1/NC2
2 Absent 0 Absent    
3 Absent 0 Absent    
4 Reduced 0 Absent    
5 Reduced þ þ Thin, rarely arching þ þ þ NC1/NC2
6 Reduced þ þ þ Thin, rarely arching þ þ þ NC1/NC2
7 Reduced þ þ Thin, rarely banded, rarely arching    
8 Absent þ Short, rudimentary þ þ þ NC1/NC2
9 Reduced þ þ Straight, non-banded þ þ þ NC1/NC2
10 Reduced þ Thin, mild arching    
11 Absent þ Short, rudimentary    
12 Reduced þ Thin and wispy  þ þ TH
13 Reduced þ Thin and wispy    
14 Normal þ þ þ þ Few banded, arching, looped    
15 Normal þ þ þ Non-banded, arching    
16 Normal þ þ þ þ þ Banded, arching  þ þ TH
17 Normal þ þ þ þ Thin, arching, looped    
18 Normal þ þ þ Non-banded, some arching þ  þ NC1/NC2
19 Normal þ þ þ þ Banded, arching  þ þ TH
20 Normal þ Very thin and straight þ þ þ NC1/NC2
21 Normal þ þ þ þ Thin and wispy, occasionally mild arching þ þ þ NC1/NC2
22 Normal þ þ þ Thin, wispy, occasional arching  þ þ TH
NHS Normal þ þ þ þ þ Thick, banded, arching, looping    
EBA    þ þ þ NC1/NC2
Abbreviations: AF, anchoring fibril; DEJ, dermal–epidermal junction; EBA, epidermolysis bullosa acquisita; NHS, normal human skin; TH, triple helical domain.
C7 expression at the DEJ was determined by immunofluorescence staining of cyrosections with an anti-NC1 antibody. AFs were evaluated by transmission electron
microscopy, with the density indicated (0 indicates that no AFs were identified; five stars indicate normal density). The morphology of the individual AFs is
qualitatively accessed from worst to best: absent, short or rudimentary, thin or wispy, arching, looping, banded, thick. Normal individuals have a 5 plus density with
thick, banded, arching, and looping AFs. ELISA was performed with either a commercially available MBL kit that uses a mixture of immobilized NC1 and NC2
domains as the target substrate or our recently developed assay that uses full-length, recombinant human C7 as the target substrate. Immunoblot analysis was
performed using purified recombinant C7.
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4–7, 9, 10, 12, 13) or no expression of
C7 (patients 2, 3, 8, 11).
AFs were evaluated by transmission
electron microscopy for density and
morphology. As summarized in Table 2
and Supplementary Figure S2 online,
RDEB patients had reduced density or
complete absence of AFs. When AFs
were observed, they appeared attenuated
in size or had an abnormal morphology.
To determine whether RDEB patients
have anti-C7 antibodies, we subjected our
RDEB patients’ sera to two different anti-
C7 antibody ELISAs and immunoblot ana-
lysis. One commercially available ELISA
utilizes NC1 and NC2 domains as the
target substrate. The second ELISA is one
we developed and employs full-length C7
as the target substrate. We used 13 EBA
sera as positive controls and sera from 17
normal subjects as negative controls to
establish the assay. The ELISA results are
shown in Supplementary Figures S3
and S4 online and summarized in
Table 2. With the commercial ELISA, 7
of 22 RDEB patient sera (patients 5, 6, 8,
9, 18, 20, 21) showed reactivity with
values above the threshold. Similarly, in
the full-length C7 ELISA, 11 of 22 patients
exhibited reactivity. Using the full-length
C7 ELISA allowed us to identify sera from
four RDEB patients (patients 12, 16, 19,
22) that exclusively recognized the TH
domain. These sera were further analyzed
by immunoblotting against purified C7
(Woodley et al., 2004a). As summarized
in Table 2 and Supplementary Figure S5
online, there is 100% correlation between
ELISA and immunoblot results.
To determine whether RDEB sera
recognize C7 in the skin, we performed
indirect immunofluorescence staining
using salt-split human skin as substrate
(Woodley et al., 1984). None of the sera
from these 11 patients bound to C7 on
the dermal side of salt-split skin (data
not shown). In addition, direct immuno-
fluorescence of the 11 patients’ skin did
not detect any anti-C7 antibody deposits
(data not shown), suggesting that the
anti-C7 antibodies in their sera are
likely non-pathogenic.
This study provides evidence that
12 of 22 bona fide RDEB patients have
low-level circulating anti-C7 autoanti-
bodies that do not bind to the patients’
skin. A previous smaller study found that
one of seven RDEB patients exhibited
anti-C7 antibodies by ELISA (Pendaries
et al., 2010). In accordance with
our data herein, a recent study of 17
RDEB patients showed that 15 of 17 of
the patients exhibited anti-C7 antibodies
(Tampoia et al., 2013). DIF on the RDEB
patients, however, was not performed in
either of these two studies.
Although our RDEB patients had vary-
ing types of COL7A1 mutations, the
expression of C7 in the DEJ of their skin
ranged from none to the same as normal
skin. The generation of anti-C7 antibodies
in our RDEB cohort did not correlate with
the expression of C7 in the patients’ skin,
the type of COL7A1 mutation, the
patients’ age, or the classification of
RDEB. It is interesting to note that a
correlation between anti-C7 antibodies
and the Birmingham EB severity score
was observed (Tampoia et al., 2013).
All therapies for RDEB including cell
therapy, protein therapy, and vector
therapy will involve exposure of the
patient to new domains of C7 and the
potential to generate anti-C7 autoanti-
bodies (Chen et al., 2002, Remington
et al., 2009; Woodley et al., 2004a, b;
Wong et al., 2008; Wagner et al., 2010).
The presence of anti-C7 antibodies in
some RDEB patients prior to treatment
should be taken into consideration
when selecting and evaluating patients
involved in clinical trials.
Written informed consent was obtai-
ned from the 22 subjects with RDEB. The
study was approved by the University of
Southern California Institutional Review
Boards and was conducted according to
the Declaration of Helsinki Principles.
CONFLICT OF INTEREST
MC, DTW, and the University of Southern Cali-
fornia hold patents for recombinant type VII col-
lagen, which are licensed by Shire Human Genetic
Therapies. MC and DTW have filed a conflict of
interest declaration with Randoph W Hall, Vice
Provost for Research Advancement at the Univer-
sity of Southern California.
ACKNOWLEDGMENTS
This work was supported by NIH grants RO1
AR47981 to MC, and RC4AR060535 and RO1
AR33625 to MC and DTW. We thank Sara Tufa for
technical support of transmission electron microscopy.
David T. Woodley1, Jon Cogan1,
Xinyi Wang1, Yingping Hou1,
Cyrus Haghighian1, Gail Kudo1,
Douglas R. Keene2 and Mei Chen1
1Department of Dermatology, Keck School of
Medicine, University of Southern California, Los
Angeles, California, USA and 2Shriner’s
Hospital for Children, Portland, Oregon, USA
E-mail: dwoodley@usc.edu or chenm@usc.edu
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Burgeson RE (1993) Type VII collagen, anchoring
fibrils, and epidermolysis bullosa. J Invest
Dermatol 101:252–5
Chen M, Kasahara N, Keene DR et al. (2002)
Restoration of type VII collagen expression
and function in dystrophic epidermolysis bul-
losa. Nat Genet 32:670–5
Chen M, Petersen MJ, Li HL et al. (1997) Ultravio-
let A irradiation upregulates type VII collagen
expression in human dermal fibroblasts.
J Invest Dermatol 108:125–8
Fine JD, Eady RA, Bauer EA et al. (2008) The
Classification of inherited epidermolysis bul-
losa (EB): report of the Third International
Consensus Meeting on Diagnosis and Classifi-
cation of EB. J Am Acad Dermatol 58:931–50
Pendaries V, Gasc G, Titeux M et al. (2010) Immune
reactivity to type VII collagen: implications for
gene therapy of recessive dystrophic epider-
molysis bullosa. Gene Therapy 17:930–7
Remington J, Wang X, Hou Y et al. (2009) Injection of
recombinant human type VII collagen corrects
the disease phenotype in a murine model of dys-
trophic epidermolysis bullosa. Mol Ther 17:26–33
Tampoia M, Bonamonte D, Filoni A et al. (2013)
Prevalence of specific anti-skin autoantibodies
in a cohort of patients with inherited epider-
molysis bullosa. Orphanet J Rare Dis 8:132
Wagner JE, Ishida-Yamamoto A, McGrath JA et al.
(2010) Bone marrow transplantation for reces-
sive dystrophic epidermolysis bullosa. N Engl
J Med 363:629–39
Wertheim-Tysarowska K, Sobczyska-Tomaszewska
A, Kowalewski C et al. (2012) The COL7A1
mutation database. Hum Mutat 33:327–31
Wong T, Gammon L, Liu L et al. (2008) Potential of
fibroblast cell therapy for recessive dystrophic
epidermolysis bullosa. J Invest Dermatol
128:2179–89
Woodley DT, Briggaman RA, O’Keefe EJ et al.
(1984) Identification of the skin basement-
membrane autoantigen in epidermolysis bul-
losa acquisita. N Engl J Med 310:1007–13
Woodley DT, Keene DR, Atha T et al. (2004a)
Injection of recombinant human type VII col-
lagen restores collagen function in dystrophic
epidermolysis bullosa. Nat Med 10:693–5
Woodley DT, Keene DR, Atha T et al. (2004b) Intra-
dermal injection of lentiviral vectors corrects
regenerated human dystrophic epidermolysis
bullosa skin tissue in vivo. Mol Ther 10:318–26
Yaoita H, Briggaman RA, Lawley TJ et al. (1981)
Epidermolysis bullosa acquisita: ultrastructural
and immunological studies. J Invest Dermatol
76:288–92
1140 Journal of Investigative Dermatology (2014), Volume 134
